Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya68207610.26442/00403660.2025.09.203375Editorial articleПередовая статьяResearch ArticleCardiology and cardiac surgery – a symbiosis of successful treatment of heart failureКардиология и кардиохирургия – симбиоз успеха лечения сердечной недостаточностиhttps://orcid.org/0000-0003-4318-0315UskachTatiana M.УскачТатьяна Марковна
Russian Federation

д-р мед. наук, проф., вед. науч. сотр. отд. заболеваний миокарда и сердечной недостаточности ФГБУ «НМИЦК им. акад. Е.И. Чазова», проф. каф. кардиологии ФГБУ ДПО РМАНПО

amanatova.v@yandex.ruhttps://orcid.org/0000-0002-0678-9538AmanatovaValeria A.АманатоваВалерия Александровна
Russian Federation

канд. мед. наук, науч. сотр. отд. заболеваний миокарда и сердечной недостаточности

amanatova.v@yandex.ruhttps://orcid.org/0000-0001-8305-1855ArdusDarin F.АрдусДарин Фаресовна
Russian Federation

канд. мед. наук, науч. сотр. лаб. хирургических и рентгенохирургических методов лечения нарушений ритма сердца отд. сердечно-сосудистой хирургии

amanatova.v@yandex.ruhttps://orcid.org/0000-0002-5186-2474SapelnikovOleg V.СапельниковОлег Валерьевич
Russian Federation

д-р мед. наук, гл. науч. сотр., рук. лаб. хирургических и рентгенохирургических методов лечения нарушений ритма сердца отд. сердечно-сосудистой хирургии

amanatova.v@yandex.ruhttps://orcid.org/0000-0002-5736-5698ImaevTimur E.ИмаевТимур Эмвярович
Russian Federation

д-р мед. наук, рук. лаб. гибридных методов лечения сердечно-сосудистых заболеваний отд. сердечно-сосудистой хирургии Института клинической кардиологии им. А.Л. Мясникова

amanatova.v@yandex.ruhttps://orcid.org/0000-0001-9234-6129TereshchenkoSergey N.ТерещенкоСергей Николаевич
Russian Federation

д-р мед. наук, проф., рук. отд. заболеваний миокарда и сердечной недостаточности ФГБУ «НМИЦК им. акад. Е.И. Чазова», зав. каф. кардиологии ФГБУ ДПО РМАНПО

amanatova.v@yandex.ruChazov National Medical Research Center of CardiologyФГБУ «Национальный медицинский исследовательский центр кардиологии им. акад. Е.И. Чазова» Минздрава РоссииRussian Medical Academy of Continuous Professional EducationФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России20102025979Issues of cardiologyВопросы кардиологии7627720306202502072025Copyright ©; 2025, Consilium MedicumCopyright ©; 2025, ООО "Консилиум Медикум"2025Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/682076

Currently, the proportion of patients with heart failure is progressively increasing. Despite the progress in drug therapy, additional manipulations are often necessary to correct cardiovascular pathology in these patients. Given the high comorbidity, the use of classical surgical techniques is impossible in some cases. Implantation of high-tech devices, catheter ablation of arrhythmogenic areas, transcatheter mitral valve plastic surgery are minimally invasive surgical methods. Proper interaction between a cardiologist and a cardiovascular surgeon allows for the maximum personalization of the approach to the treatment of each patient, achieving maximum results with significantly reduced risks.

В настоящее время прогрессивно увеличивается доля пациентов с сердечной недостаточностью. Несмотря на прогресс в медикаментозной терапии, часто необходимы дополнительные манипуляции для коррекции сердечно-сосудистой патологии у данных больных. Учитывая высокую коморбидность, применение методик классической хирургии невозможно в ряде случаев. Имплантация высокотехнологичных устройств, катетерная аблация аритмогенных участков, транскатетерная пластика митрального клапана являются малоинвазивными хирургическими методами. Правильное взаимодействие кардиолога и сердечно-сосудистого хирурга позволяет максимально персонифицировать подход к лечению каждого пациента, добиваясь лучшего результата при существенном снижении рисков.

chronic heart failureimplantable devicesradiofrequency ablationmitral regurgitationtranscatheter mitral valve repairхроническая сердечная недостаточностьимплантируемые устройстварадиочастотная аблациямитральная недостаточностьтранскатетерная пластика митрального клапанаГалявич А.С., Терещенко С.Н., Ускач Т.М., и др. Хроническая сердечная недостаточность. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(11):6162 [Galyavich AS, Tereshchenko SN, Uskach TM, et al. 2024 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2024;29(11):6162 (in Russian)]. DOI:10.15829/1560-4071-2024-6162McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. DOI:10.1056/NEJMoa1409077Gattis WA, O'Connor CM, Leimberger JD, et al. Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. Am J Cardiol. 2003;91(2):169-74. DOI:10.1016/s0002-9149(02)03104-1Wikstrand J, Wedel H, Castagno D, McMurray JJ. The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF. J Intern Med. 2014;275(2):134-43. DOI:10.1111/joim.12141Simko F, Bada V, Simková M, et al. The significance of aldosterone in chronic heart failure: the RALES study. Vnitr Lek. 2002;48(8):767-72. DOI:10.1093/eurheartj/16.suppl_n.107McMurray JJV, DeMets DL, Inzucchi SE, et al. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail. 2019;21(5):665-75. DOI:10.1002/ejhf.1432Anker SD, Butler J, Filippatos G, et al. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial. Circulation. 2021;143(4):337-49. DOI:10.1161/CIRCULATIONAHA.120.051824McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. DOI:10.1093/eurheartj/ehab368Maddox TM, Januzzi Jr JL, Allen LA, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2021;77(6):772-810. DOI:10.1016/j.jacc.2020.11.022Viola F, Del Corso G, De Paulis R, et al. GPU accelerated digital twins of the human heart open new routes for cardiovascular research. Sci Rep. 2023;13:8230. DOI:10.1038/s41598-023-34098-8Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361(14):1329-38. DOI:10.1056/NEJMoa09064312021 Рекомендации ESC по электрокардиостимуляции и сердечной ресинхронизирующей терапии. Российский кардиологический журнал. 2022;27(7):5159 [2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Russian Journal of Cardiology. 2022;27(7):5159 (in Russian)]. DOI:10.15829/1560-4071-2022-5159Ruschitzka F, Abraham WT, Singh JP, et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med. 2013;369(15):1395-405. DOI:10.1056/NEJMoa1306687Anker SD, Borggrefe M, Neuser H, et al. Cardiac contractility modulation improves long-term survival and hospitalizations in heart failure with reduced ejection fraction. Eur J Heart Fail. 2019;21(9):1103-13. DOI:10.1002/ejhf.1374Fastner C, Yuecel G, Rudic B, et al. Cardiac Contractility Modulation in Patients with Ischemic versus Non-ischemic Cardiomyopathy: Results from the MAINTAINED Observational Study. Int J Cardiol. 2021;342:49-55. DOI:10.1016/j.ijcard.2021.07.048Wiegn P, Chan R, Jost C, et al. Safety, Performance, and Efficacy of Cardiac Contractility Modulation Delivered by the 2-Lead Optimizer Smart System: The FIX-HF-5C2 Study. Circ Heart Fail. 2020;13(4):e006512. DOI:10.1161/CIRCHEARTFAILURE.119.006512Kadish A, Nademanee K, Volosin K, et al. A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. Am Heart J. 2011;161:329-37.e2. DOI:10.1016/j.ahj.2010.10.025Сафиуллина А.А., Ускач Т.М., Сапельников О.В., и др. Модуляция сердечной сократимости у пациентов с хронической сердечной недостаточностью со сниженной фракцией выброса: метаанализ данных российских клинических исследований. Кардиоваскулярная терапия и профилактика. 2025:24(3):105-15 [Safiullina AA, Uskach TM, Sapelnikov OV, et al. Cardiac contractility modulation in patients with heart failure with reduced ejection fraction: a meta-analysis of Russian clinical trials. Cardiovascular Therapy and Prevention. 2025;24(3):105-15 (in Russian)]. DOI:10.15829/1728-8800-2025-4191Santangeli P, Rame JE, Birati EY, Marchlinski FE. Management of Ventricular Arrhythmias in Patients With Advanced Heart Failure. J Am Coll Cardiol. 2017;69(14):1842-60. DOI:10.1016/j.jacc.2017.01.047Wong CX, Brown A, Lau DH, et al. Epidemiology of Sudden Cardiac Death: Global and Regional Perspectives. Heart Lung Circ. 2019;28(1):6-14. DOI:10.1016/j.hlc.2018.08.026Bokhari F, Newman D, Greene M, et al. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS). Circulation. 2004;110(2):112-6. DOI:10.1161/01.CIR.0000134957.51747.6EMoss AJ, Zareba W, Hall WJ, et al. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877-83. DOI:10.1056/NEJMoa013474Wasiak M, Tajstra M, Kosior D, Gąsior M. An implantable cardioverter-defibrillator for primary prevention in non-ischemic cardiomyopathy: A systematic review and meta-analysis. Cardiol J. 2023;30(1):117-24. DOI:10.5603/CJ.a2021.0041Dijkshoorn LA, Smeding L, Pepplinkhuizen S, et al. Fifteen years of subcutaneous implantable cardioverter-defibrillator therapy: Where do we stand, and what will the future hold? Heart Rhythm. 2025;22(1):150-8. DOI:10.1016/j.hrthm.2024.06.028Аманатова В.А., Ускач Т.М., Гришин И.Р., и др. Вопросы безопасности подкожных систем кардиовертера-дефибриллятора: все ли так просто и однозначно? Вестник аритмологии. 2024;31(117):33-40 [Amanatova VA, Uskach TM, Grishin IR, et al. Safety issues of subcutaneous cardioverter-defibrillator systems. Is everything so simple and definitely? Journal of Arrhythmology. 2024;31(3):33-40 (in Russian)]. DOI:10.35336/VA-1357Кулешова М.В., Ускач Т.М., Сапельников О.В. Внезапная сердечная смерть и декомпенсация сердечной недостаточности: как можно снизить риски. Терапевтический архив. 2025;97(1):80-5 [Kuleshova MV, Uskach TM, Sapelnikov OV. Sudden cardiac death and decompensation of heart failure: how to reduce the risks. A review. Terapevticheskii Arkhiv (Ter. Arkh.). 2025;97(1):80-5 (in Russian)]. DOI:10.26442/00403660.2025.01.203031Аманатова В.А., Ускач Т.М., Гришин И.Р., и др. Комплексный подход к лечению хронической сердечной недостаточности: имплантация подкожной системы кардиовертера-дефибриллятора и модулятора сердечной сократимости. Клинический случай. Вестник аритмологии. 2024;31(4):75-81 [Amanatova VA, Uskach TM, Grishin IR, et al. Multipurpose approach to the treatment of chronic heart failure: implantation of system subcutaneous cardioverter-defibrillator and cardiac contractility modulation device. A case report. Journal of Arrhythmology. 2024;31(4):75-81 (in Russian)]. DOI:10.35336/VA-1365Белов Ю.В., Чарчан Э.Р., Салагаев Г.И. Функциональная митральная недостаточность у больных с аортальными пороками сердца: современное состояние проблемы. Кардиология и сердечно-сосудистая хирургия. 2016;9(1):69-75 [Belov YuV, Charchian ÉR, Salagaev GI. Functional mitral regurgitation in aortic valve disease patients: state of the art. Russian Journal of Cardiology and Cardiovascular Surgery. 2016;9(1):69 75 (in Russian)]. DOI:10.17116/kardio20169169-75Maddox TM, Januzzi Jr JL, Allen LA. 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction J Am Coll Cardiol. 2024;83(15):1444-88. DOI:10.1016/j.jacc.2023.12.024Pagnesi M, Adamo M, Sama IE, et al. Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT-CHF. Eur J Heart Fail. 2021;23(10):1750-8. DOI:10.1002/ejhf.2276Chehab O, Roberts-Thomson R, Ng Yin Ling C, et al. Secondary mitral regurgitation: pathophysiology, proportionality and prognosis. Heart. 2020;106(10):716-23. DOI:10.1136/heartjnl-2019-316238Silbiger JJ. Mechanistic insights into ischemic mitral regurgitation: echocardiographic and surgical implications. J Am Soc Echocardiogr. 2011;24(7):707-19. DOI:10.1016/j.echo.2011.04.001Zoghbi WA, Levine RA, Flachskampf F, et al. Atrial functional mitral regurgitation. JACC: cardiovascular imaging expert panel viewpoint. JACC Cardiovasc Imaging. 2022;15(11):1870-82. DOI:10.1016/j.jcmg.2022.08.016Имаев Т.Э., Комлев А.Е., Кучин И.В., Акчурин Р.С. Транскатетерные методы лечения патологии митрального клапана: современное состояние проблемы. Часть 1. Кардиологический вестник. 2020;15(1):4-11 [Imaev TE, Komlev AE, Kuchin IV, Akchurin RS. Transcatheter methods of treatment of mitral valve pathology: current state of the problem. Kardiologicheskii vestnik. 2020;15(1):4-11 (in Russian)]. DOI:10.36396/MS.2020.16.1.001Maisano F, Torracca L, Oppizzi M, et al. The edge-to-edge technique: a simplified method to correct mitral insufficiency. Eur J Cardio-Thorac Surg. 1998;13(3):240-6. DOI:10.1016/s1010-7940(98)00014-1Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011;365(2):189. DOI:10.1056/NEJMoa1009355Iung B, Armoiry X, Vahanian A, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years. Eur Opean J Heart Fail. 2019;21(12):1619-27. DOI:10.1002/ejhf.1616Stone GW, Lindenfeld JA, Abraham WT. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med. 2018;379:2307-18. DOI:10.1056/NEJMoa1806640.Голухова Е.З., Скопин И.И., Латышев М.С., Сливнева И.В. Интервенционная реконструкция митрального клапана «край-в-край». Патология кровообращения и кардиохирургия. 2022;26(1):9-23 [Golukhova EZ, Skopin II, Latyshev MS, Slivneva IV. Percutaneous mitral edge-to-edge repair. Circulation Pathology and Cardiac Surgery. 2022;26(1):9-23 (in Russian)]. DOI:10.21688/1681-3472-2022-1-9-23Baldus S, Doenst T, Pfister R, et al. Transcatheter repair versus mitral-valve surgery for secondary mitral regurgitation. N Engl J Med. 2024;391(19):1787-98. DOI:10.1056/NEJMoa2408739Anker SD, Friede T, von Bardeleben RS, et al. Transcatheter valve repair in heart failure with moderate to severe mitral regurgitation. N Engl J Med. 2024;391(19):1799-809. DOI:10.1056/NEJMoa2314328Mundisugih J, Franke KB, Tully PJ, et al. Prevalence and Prognostic Implication of Atrial Fibrillation in Heart Failure Subtypes: Systematic Review and Meta-Analysis. Heart Lung Circ. 2023;32(6):666-77. DOI:10.1016/j.hlc.2023.02.009Guisado-Espartero ME, Salamanca-Bautista P, Aramburu-Bodas Ó, et al. RICA investigators group. Heart failure with mid-range ejection fraction in patients admitted to internal medicine departments: Findings from the RICA Registry. Int J Cardiol. 2018;255:124-8. DOI:10.1016/j.ijcard.2017.07.101Newman JD, O'Meara E, Böhm M, et al. Implications of Atrial Fibrillation for Guideline-Directed Therapy in Patients With Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2024;83(9):932-50. DOI:10.1016/j.jacc.2023.12.033Yang E, Heckbert SR, Ding J, et al. Prevalence of Subclinical Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail. 2024;12(3):492-504. DOI:10.1016/j.jchf.2023.09.023Rillig A, Magnussen C, Ozga AK, et al. Early Rhythm Control Therapy in Patients With Atrial Fibrillation and Heart Failure. Circulation. 2021;144(11):845-58. DOI:10.1161/CIRCULATIONAHA.121.056323Kim D, Yu HT, Kwon OS, et al. Effect of epicardial fat volume on outcomes after left atrial posterior wall isolation in addition to pulmonary vein isolation in patients with persistent atrial fibrillation. Front Cardiovasc Med. 2022;9:1005760. DOI:10.3389/fcvm.2022.1005760DeBerge M, Shah SJ, Wilsbacher L, et al. Macrophages in Heart Failure with Reduced versus Preserved Ejection Fraction. Trends Mol Med. 2019;25(4):328-40. DOI:10.1016/j.molmed.2019.01.002Wyse DG, Waldo AL, DiMarco JP, et al. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825-33. DOI:10.1056/NEJMoa021328Терещенко С.Н., Ускач Т.М. Стратегии лечения пациентов с фибрилляцией предсердий и сердечной недостаточностью. Терапевтический архив. 2021;93(12):1545-50 [Tereshchenko SN, Uskach TM. Treatment strategies for patients with atrial fibrillation and chronic heart failure. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(12):1545-50 (in Russian)]. DOI:10.26442/00403660.2021.12.201205Hagens VE, Crijns HJ, Van Veldhuisen DJ, et al. RAte Control versus Electrical cardioversion for persistent atrial fibrillation study group. Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAte Control versus Electrical cardioversion (RACE) study. Am Heart J. 2005;149(6):1106-11. DOI:10.1016/j.ahj.2004.11.030Heidenreich PA, Bozkurt B, Aguilar D, et al. ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. DOI:10.1161/CIR.0000000000001063Van Gelder IC, Groenveld HF, Crijns HJGM, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362(15):1363-73. DOI:10.1056/NEJMoa1001337Hunter RJ, Berriman TJ, Diab I, et al. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). Circ Arrhythm Electrophysiol. 2014;7(1):31-8. DOI:10.1161/CIRCEP.113.000806Prabhu S, Taylor AJ, Costello BT, et al. Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction: The CAMERA-MRI Study. J Am Coll Cardiol. 2017;70(16):1949-61. DOI:10.1016/j.jacc.2017.08.041Di Biase L, Mohanty P, Mohanty S, et al. Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial. Circulation. 2016;133(17):1637-44. DOI:10.1161/CIRCULATIONAHA.115.019406Marrouche NF, Brachmann J, Andresen D, et al. CASTLE-AF Investigators. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med. 2018;378(5):417-27. DOI:10.1056/NEJMoa1707855Packer DL, Piccini JP, Monahan KH, et al. CABANA Investigators. Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure: Results From the CABANA Trial. Circulation. 2021;143(14):1377-90. DOI:10.1161/CIRCULATIONAHA.120.050991Sohns C, Fox H, Marrouche NF, et al. CASTLE HTx Investigators. Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation. N Engl J Med. 2023;389(15):1380-9. DOI:10.1056/NEJMoa2306037Moersdorf M, Tijssen JGP, Marrouche NF, et al. CASTLE HTx Investigators. Prognosis of patients in end-stage heart failure with atrial fibrillation treated with ablation: Insights from CASTLE-HTx. Heart Rhythm. 2024;21(7):1008-15. DOI:10.1016/j.hrthm.2024.04.013Van Gelder IC, Rienstra M, Bunting KV, et al. ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314. DOI:10.1093/eurheartj/ehae176Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1-156. DOI:10.1161/CIR.0000000000001193Tzeis S, Gerstenfeld EP, Kalman J, et al. 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. 2024;26(4):euae043. DOI:10.1093/europace/euae043Turagam M, Neuzil P, Schmidt B., et al. Safety and Effectiveness of Pulsed Field Ablation for Atrial Fibrillation in Patients With Heart Failure. J Am Coll Cardiol EP. 2024;7(2):1675-86. DOI:10.1016/j.jacep.2024.05.002Polovina M, Tschöpe C, Rosano G, et al. Incidence, risk assessment and prevention of sudden cardiac death in cardiomyopathies. Eur J Heart Fail. 2023;25(12):2144-63. DOI:10.1002/ejhf.3076Amoni M, Dries E, Ingelaere S, Vermoortele D, et al. Ventricular Arrhythmias in Ischemic Cardiomyopathy-New Avenues for Mechanism-Guided Treatment. Cells. 2021;10(10):2629. DOI:10.3390/cells10102629Kahle AK, Jungen C, Alken FA, et al. Management of ventricular tachycardia in patients with ischaemic cardiomyopathy: contemporary armamentarium. 2022;24(4):538-51. DOI:10.1093/europace/euab274Лебедев Д.С., Михайлов Е.Н., Неминущий Н.М., и др. Желудочковые нарушения ритма. Желудочковые тахикардии и внезапная сердечная смерть. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(7):4600 [Lebedev DS, Mikhailov EN, Neminuschiy NM, et al. Ventricular arrhythmias. Ventricular tachycardias and sudden cardiac death. 2020 Clinical guidelines. Russian Journal of Cardiology. 2021;26(7):4600 (in Russian)]. DOI:10.15829/1560-4071-2021-4600Stevenson WG, Richardson TD, Kanagasundram AN, et al. State of the Art: Mapping Strategies to Guide Ablation in Ischemic Heart Disease. JACC Clin Electrophysiol. 2024;10(12):2744-61. DOI:10.1016/j.jacep.2024.09.016Virk SA, Kumar S. Catheter Ablation of Ventricular Tachycardia in Patients With Structural Heart Disease: A Meta-Analysis. JACC Clin Electrophysiol. 2023;9(2):255-7. DOI:10.1016/j.jacep.2022.09.002Tung R, Xue Y, Chen M, et al. PAUSE-SCD Investigators. First-Line Catheter Ablation of Monomorphic Ventricular Tachycardia in Cardiomyopathy Concurrent With Defibrillator Implantation: The PAUSE-SCD Randomized Trial. Circulation. 2022;145(25):1839-49. DOI:10.1161/CIRCULATIONAHA.122.060039Sapp JL, Tang ASL, Parkash R, et al. VANISH2 Study Team. Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia. N Engl J Med. 2025;392(8):737-47. DOI:10.1056/NEJMoa2409501Huang K, Bennett RG, Campbell T, et al. Early Catheter Ablation Versus Initial Medical Therapy for Ventricular Tachycardia Storm. Circ Arrhythm Electrophysiol. 2022;15(12):e011129.